•  home page
  •  location & contact
  • Español
entrechem entrechem
  • about us
    • founders
    • key personnel
    • funding
    • strategy
  • pipeline
    • pipeline chart
    • EC-8042
    • EC-70124
  • technology
    • natural products
    • synthetic biology
    • biocatalysis
      • DA · enantiomerically pure chiral diamines
      • AA · enantiomerically pure chiral amino alcohols
      • IA · enantiomerically pure chiral amino indanes
  • collaborations
    • scientific collaborators
    • collaborative projects
  • publications
    • EC-8042
    • EC-70124
    • biocatalysis
    • synthetic biology
  • news
entrechem entrechem
  • about us
    • founders
    • key personnel
    • funding
    • strategy
  • pipeline
    • pipeline chart
    • EC-8042
    • EC-70124
  • technology
    • natural products
    • synthetic biology
    • biocatalysis
      • DA · enantiomerically pure chiral diamines
      • AA · enantiomerically pure chiral amino alcohols
      • IA · enantiomerically pure chiral amino indanes
  • collaborations
    • scientific collaborators
    • collaborative projects
  • publications
    • EC-8042
    • EC-70124
    • biocatalysis
    • synthetic biology
  • news
Mar 01

EntreChem participates in the EU project «BIOCASCADES – Sustainable and Scalable Biocatalytic Cascade Reactions Training Network»

Seven universities and five industrial partners from five European countries to cooperate in the project. The European Commission has awarded €2.7 million to the H2020 project «BIOCASCADES - Sustainable and Scalable Biocatalytic Cascade Reactions Training Network». The project is under the Marie Skłodowska- Curie Innovative Training Networks, specifically in the... read more →
  • 1 March, 2015
  • Projects
Sep 26

EntreChem presents in ESMO 2014 congress: Activity of the multi-targeted kinase inhibitor EC-70124 in colorectal cancer

Colorectal cancer (CRC) shows alterations on the activation status of receptor tyrosine kinases (RTKs) and intracellular cytoplasmic kinases, some of which correlate between primary tumors and liver metastases. EC-70124, a kinase inhibitor being developed at EntreChem SL, shows strong antiproliferative effect on CRC by acting on relevant activated targets observed... read more →
  • 26 September, 2014
  • Research
Jun 02

EntreChem presents in 2014 ASCO Annual Meeting: Activity of the multi-targeted kinase inhibitor EC-70124 in Triple Negative Breast Cancer

Triple Negative Breast Cancer (TNBC) at the molecular level shows alterations on receptor tyrosine kinases (RTKs), downstream signaling pathways involved in the regulation of proliferation and survival, and DNA repair machinery. EC-70124, a kinase inhibitor being developed at EntreChem SL, shows a multi-mode of action on TNBC by inhibiting several... read more →
  • 2 June, 2014
  • Research
Jan 08

EntreChem participates in the synthetic biology project «STREPSYNTH»

EntreChem participates in the FP7 European Collaborative Project STREPSYNTH, whose goal is rewiring Streptomyces bacteria as a cell factory for the cost-effective production of biomolecules. The project has been awarded in the last KBBE-FP7 call that focused on synthetic biology, a topic of current high interest both in industry and... read more →
  • 8 January, 2014
  • Projects
Apr 15

Orally active Entrechem’s kinase inhibitor EC-70124 targets prostate tumors overexpressing ESE1/ELF3 and NF-kB

ESE1/ELF3 and NF-kB are co-activated in selected prostate tumors and associated with adverse prognosis in prostate tumors, according to researchers at the IOR (Switzerland). EC-70124, a kinase inhibitor being developed at EntreChem SL, has shown efficacy when administered orally in a murine model of prostate cancer whose malignant phenotype depends... read more →
  • 15 April, 2013
  • Research
Jun 22

EntreChem closed a financing round totaling 1 million EUR

EntreChem closed a financing round totaling 1 million EUR ($1.25M) with existing shareholders of the company. This all-private funding significantly strengthens the capacities of research and development of the biotech company. These capital contributions help keep 100% ownership under local control, with Francisco Moris confirmed as Managing Director of the... read more →
  • 22 June, 2012
  • Financing
Apr 16

EntreChem’s mithralogs show increased potency and higher selectivity for treatment of sarcoma

The fusion protein EWS-FLI1 ins a constitutively activated transcription factor responsible for the oncogenic phenotype of Ewing sarcoma. Mithramycin was identified last year out of 50.000 compounds as a potent inhibitor of EWS-FLI1, according to researchers at the National Cancer Institute and Vanderbilt University (USA). EC-8042, a mithramycin analog (mithralog)... read more →
  • 16 April, 2012
  • Research
Mar 26

EntreChem’s kinase inhibitor shows potential for treatment of head and neck cancer

The PI3K/Akt/PTEN molecular pathway is frequently mutated in this type of tumor, where activation of the Akt kinase is a poor prognosis factor, according to researchers at CIEMAT. EC-70124, a kinase inhibitor under development at EntreChem SL, has shown efficacy in a murine model of Head & Neck cancer that... read more →
  • 26 March, 2012
  • Research
May 09

EntreChem’s developmental drug opens the door to a new strategy for glioblastoma

Glioblastoma initiating cells activate NFkB cell signaling pahtway to avoid terminal differentiation, according to researchers in Hospital Valdecilla. EC-70124, an inhibitor of NfkB pathway under development at EntreChem SL, has shown efficacy in murine models of glioblastoma. A multidisciplinar research team from EntreChem SL (Oviedo), Valdecilla Hospital (Santander), University of... read more →
  • 9 May, 2011
  • Research
Dec 30

Dr Jesús Cortés joins EntreChem as Director of Molecular Biology

EntreChem announces that Dr Jesús Cortés has joined the company as Director of Molecular Biology. A native of Mexico, Dr Cortés holds a PhD in Microbiology by the University of León, Spain, and has been working in the UK for the last 23 years. During his stay in Cambridge University... read more →
  • 30 December, 2010
  • Other
  • 1
  • 2
  • 3
  • 4

« Previous Page — Next Page »

latest news

  • AI-Therapeutics acquires the preclinical drugs EC-8042 and EC-70124 from EntreChem SL
  • EC-8042 targets SWI/SNF complex vulnerabilities and induces epigenetic reprogramming and permanent cures in rhabdoid tumor
  • EntreChem participates in the ERA-Co-Biotech project «MISSION»

categories

  • Agreements
  • Financing
  • Projects
  • Publications
  • Research
  • Other

archive

EntreChem, S.L.

Vivero Ciencias de la Salud,
c/ Colegio Santo Domingo de Guzmán s/n,
33011 Oviedo, Spain

info@entrechem.com

pipeline  /  chart
· EC-8042
· EC-70124

scientific collaborators
collaborative projects

  • about us
  • technology
  • publications
  • news
Copyright © 2023 EntreChem, S.L. All rights reserved.
  • privacy policy
  • usage policy
  • cookies policy

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Privacy Overview
entrechem

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Cookie Policy

You can consult our cookies policy for more information.